Overview of Bonjesta

Property	Description
Active ingredient	Doxylamine Succinate and Pyridoxine Hydrochloride
Form	Extended-release tablet
Pharmacological class	Combination Antiemetic, H1-Antihistamine / Vitamin
General purpose	Relief from persistent nausea and vomiting
Origin	Synthetic (Doxylamine) and Essential Nutrient (Pyridoxine)

What Type of Medicine is Bonjesta?

Bonjesta is a specific prescription medicine formulated as a single, oral extended-release tablet, classified pharmaceutically as a combination antiemetic agent. It contains two distinct active pharmaceutical ingredients (APIs): Doxylamine succinate and Pyridoxine hydrochloride (a form of Vitamin B₆). The Doxylamine succinate component is a synthetic first-generation antihistamine that contributes to the anti-nausea effects by acting on histamine receptors. This product is a specific formulation designed for the pregnant patient group, an area where the combination has received clinical recognition for its efficacy and safety profile.

Composition and Unique Extended-Release Form

The medication is composed of Doxylamine succinate and Pyridoxine hydrochloride, a fixed-dose combination utilized to address persistent nausea. The product's physical form is a specialized film-coated tablet designed for oral administration, utilizing a unique release profile to sustain therapeutic levels. This extended-release characteristic ensures the active components are absorbed slowly over time, a differentiating factor from standard immediate-release formulations of the same active ingredients.

General Purpose and Therapeutic Concept

The general purpose of this product is to provide continuous, dual-action relief from persistent nausea and vomiting through its overall antiemetic action. The antihistamine component works to mitigate signals that trigger nausea in the central nervous system, while the Vitamin B₆ component supports the overall anti-sickness effect. The core therapeutic concept is centered on utilizing this combined, sustained activity to effectively manage the symptoms that can disrupt daily life for the target patient group.

Regulatory References

Doxylamine and Pyridoxine: MedlinePlus Drug Information

What side effects are possible with Bonjesta?

The official safety profile for this prescription medicine is defined by adverse reactions, frequency classifications, and necessary safety constraints as documented in regulatory sources.

Adverse Reaction Scope

Category	Official Regulatory Documentation Summary
Key adverse reaction categories	Central Nervous System (CNS) effects, Gastrointestinal disturbances, and Anticholinergic manifestations.
Frequency classification	The most frequently reported effect is Common (occurring in at least 1 out of 100 but less than 1 out of 10 users) for somnolence (drowsiness) [FDA Full Prescribing Information].
System-organ classes involved	Adverse events are documented across Nervous System Disorders (e.g., somnolence, headache, dizziness) and Gastrointestinal Disorders (e.g., dry mouth, constipation, abdominal pain).
Serious adverse reactions	The documented risks include significant CNS depression, particularly when used with alcohol or other CNS depressants. The anticholinergic properties pose risks for individuals with conditions such as angle-closure glaucoma or urinary retention [FDA Full Prescribing Information].

Safety Considerations and Constraints

Contraindications and Limitations

Use is contraindicated in patients who are currently using or have recently used (within 14 days) a Monoamine Oxidase (MAO) inhibitor due to the potential to intensify the CNS depressant effects. Caution is required in patients with pre-existing conditions sensitive to anticholinergic effects, including stenosing peptic ulcer, pyloroduodenal obstruction, and bladder-neck obstruction.

Time-Related and Population-Specific Notes

Official labeling indicates that somnolence may be more pronounced at the beginning of treatment. Furthermore, the safety and effectiveness have not been established in children under 18 years of age. Use is not recommended for women who are breastfeeding as the doxylamine component may pass into breast milk, potentially causing sedation or irritability in the infant.

Overdose and Emergency Response

If you take too much of this medication (overdose), immediate medical attention is required regardless of the severity of symptoms, as severe overdose may lead to death.

Overdose Symptoms and Presentations

Because this is an extended-release formulation, the signs of intoxication or overdose may not be apparent immediately. The documented physiological effects of an overdose primarily involve the Central Nervous System (CNS) and anticholinergic effects.

Early to Moderate Symptoms May Include:

Restlessness
Sleepiness or unusual drowsiness
Dizziness, vertigo, or lightheadedness
Dryness of mouth
Dilated pupils
Fast or pounding heart rate (tachycardia)
Mental confusion

Severe Symptoms That May Lead to Death Include:

Seizures
Cardiorespiratory arrest (particularly noted in children)
Muscle pain or weakness
Changes in urination and fluid build-up in the body

Required Emergency Actions

Due to the potential for fatal outcomes from severe intoxication, especially in children, urgent action is necessary. If you suspect an overdose, immediately call your local poison control center or emergency services. Fatalities have been reported from doxylamine overdose in children, who appear to be at a high risk for severe cardiorespiratory complications. Emergency management is primarily supportive and focused on monitoring and stabilizing vital signs.

Therapeutic Uses of Bonjesta

The primary therapeutic function of this medication is to provide targeted, prescription support for the symptomatic management of Nausea and Vomiting of Pregnancy (NVP). This combination therapy is used in pregnant women whose symptoms have not improved after dietary changes or other non-medicine treatments.

Addressing Nausea and Vomiting in Pregnancy

The medication is applied in situations involving certain distressing symptoms to address symptom clusters that may become intense or disruptive. It is considered relevant for easing challenging symptoms when they are categorized as mild to moderate in severity, used across conditions presenting with episodic manifestations. The medication helps address the persistent, pervasive sensation of nausea, along with the physical manifestations of vomiting and retching episodes.

Providing Sustained Symptomatic Relief

The principal benefit for the patient is the support that helps ease the overall symptom load. This continuous therapeutic effect may assist with maintaining functional stability when symptoms interfere with routine activities, supporting patients during symptomatic phases and contributing to easing the overall symptom load. It supports general well-being during periods of heightened symptoms and may offer supportive relief during episodes of discomfort.

Quick Fact: Supportive relief for Nausea and Vomiting of Pregnancy (NVP).

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Bonjesta?

Bonjesta is a prescription medication with strictly defined eligibility criteria based on regulatory labeling.

Approved and Non-Eligible Populations

Eligibility Status	Patient Group Defined by Official Labeling
Intended Use	Pregnant women with Nausea and Vomiting of Pregnancy (NVP) whose symptoms are not controlled by conservative management.
Contraindicated	Women with known hypersensitivity to doxylamine, pyridoxine, related antihistamines, or any component.
Contraindicated	Women concurrently using Monoamine Oxidase Inhibitors (MAOIs).
Use Not Established	Children under 18 years of age.
Not Recommended	Women who are breastfeeding.

Conditions Requiring Caution

Use of Bonjesta requires caution in women with pre-existing medical conditions that may be sensitive to its anticholinergic properties, such as narrow-angle glaucoma, certain forms of gastrointestinal obstruction (e.g., stenosing peptic ulcer, pyloroduodenal obstruction), bladder-neck obstruction, or asthma.

Limitations of Use

Bonjesta has not been studied for use in the most severe form of NVP, hyperemesis gravidarum, and its safety and effectiveness in this patient population are not known.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Bonjesta (doxylamine succinate and pyridoxine hydrochloride) as stated in government regulatory labeling.

Contraindicated Combinations and Enhanced Effects

Co-administration with Monoamine Oxidase (MAO) inhibitors is formally contraindicated. This restriction is due to the potential for MAO inhibitors to intensify and prolong the adverse central nervous system (CNS) effects of the doxylamine component.

Pharmacodynamic Interactions and Restrictions

Central Nervous System (CNS) depressants, including alcohol, certain sedating medications, opiates, and other antihistamines, should not be co-administered. This combination can result in severe additive somnolence (drowsiness), which is a pharmacodynamic effect documented in official prescribing information.

Administration Timing and Laboratory Interference

Official labeling includes specific administration requirements regarding food. The medicine must be taken on an empty stomach with water, as directed in the drug-food interaction section of the label. Furthermore, the presence of doxylamine succinate has been associated with reports of false positive results in urine screening tests for specific substances, including Methadone, Opiates, and Phencyclidine Phosphate (PCP).

Mechanism of Action

The antiemetic action of this combination drug is achieved through two complementary mechanistic domains that target the central control of the emetic reflex.

Central Blockade of Histamine H1 Receptors

The Doxylamine component exerts its effect through competitive antagonism at histamine H1 receptors (H1R) located in the brain, particularly within the Chemoreceptor Trigger Zone (CTZ) and the vestibular system. By binding to and blocking these targets, the drug interrupts the emetic signaling pathway, modulating input from the CTZ to the brain's Vomiting Center. This direct action on CNS receptors produces a reduction in the transmission of central emetic signals, which modulates the activity of the reflex control system.

Neurochemical Modulation and Cofactor Support

The Pyridoxine ( Vitamin B6) component acts as a precursor to an essential enzymatic cofactor, Pyridoxal-5-Phosphate (PLP), which is necessary for the synthesis and metabolism of CNS neurotransmitters, including serotonin and GABA. This mechanism contributes to the neurochemical balance by providing necessary enzymatic cofactor support for neuronal metabolism. This complementary action contributes to the modulation of the emetic threshold and enhances the overall systemic effect produced by the primary receptor blockade.

Dosage and Administration Information

How to Use Bonjesta: Administration Guidelines

Bonjesta (Doxylamine succinate and Pyridoxine hydrochloride) is a prescription medicine administered orally as a specialized extended-release tablet. The fixed dose in each tablet is 20 mg of Doxylamine succinate and 20 mg of Pyridoxine hydrochloride. The drug is intended for continuous, daily use and must not be taken on an as-needed basis.

Standard Dosing Regimen

The standard protocol follows a stepwise approach, starting with one tablet daily and adjusting based on the patient’s clinical response. The tablet must be taken on an empty stomach with water to prevent a delay in the onset of action.

Dosing Step	Timing and Frequency
Starting Dose (Day 1)	One extended-release tablet taken at bedtime
Maximum Dose	One tablet in the morning and one tablet at bedtime (Two tablets total per day)

Administration Requirements

To ensure the active ingredients are released slowly over the prescribed interval, the extended-release tablet must be swallowed whole. It is a critical procedural instruction that the tablet must not be crushed, chewed, or split. The use of this medication must be reassessed for continued necessity as the patient's condition progresses. If a dose is missed, it is recommended to resume the next scheduled dose at the usual time; doubling the next dose is not recommended. The safety and efficacy of Bonjesta have not been established in patients under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bonjesta

Evidence for Use in Nausea and Vomiting of Pregnancy (NVP)

The primary clinical evaluation for the combination of doxylamine and pyridoxine was studied for women experiencing Nausea and Vomiting of Pregnancy (NVP) after initial, non-medicine approaches (like dietary changes) were first tried. Research exploring short-term symptom changes for this combination primarily used Randomized Controlled Trials (RCTs).

These trials research examined a change in outcomes related to physical discomfort by using a dedicated scoring system known as the Pregnancy Unique-Quantification of Emesis (PUQE) Score. The studies explored short-term symptom changes, and findings describe patterns observed in the studies over the defined time intervals, typically around 14 to 15 days.

The specific extended-release formulation (Bonjesta) was evaluated in Bioequivalence Trials. These trials focused on comparing how the body absorbed this specific product to a similar, previously approved delayed-release version of the same active ingredients. This type of research contributes to the broader evidence landscape by using study data that suggests the product's release profile and overall drug exposure were comparable to the established combination.

Long-Term Evidence and Fetal Follow-up

Beyond short-term symptom research, the combination was observed in large-scale Epidemiological and Observational Studies. The outcomes tracked in this research were primarily related to long-term fetal outcomes, as the combination was studied for conditions characterized by fluctuating symptoms that typically occur in the first trimester. The observational data collected from thousands of pregnant women data show patterns related to the incidence of birth defects.

However, there is limited information for long-term outcomes regarding developmental outcomes or health status extending far beyond infancy. Additionally, the medication was not studied for individuals presenting with the most extreme condition, known as hyperemesis gravidarum.

Key Studies & References The Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum (RCOG Green-top Guideline No. 69)

Frequently Asked Questions (FAQ)

Common questions about Bonjesta (FAQ)

Q: How is Bonjesta different from Diclegis?

A: Bonjesta and Diclegis contain the same two active ingredients, doxylamine succinate and pyridoxine hydrochloride. The main difference lies in the formulation and strength. Bonjesta is an extended-release tablet that comes in a 20 mg/20 mg strength, while Diclegis is a delayed-release tablet available in a 10 mg/10 mg strength. Both are indicated to manage nausea and vomiting of pregnancy (NVP).

Q: Does Bonjesta cure morning sickness completely?

A: Bonjesta is indicated for the treatment and management of nausea and vomiting of pregnancy (NVP) in women whose symptoms are not controlled by non-medical approaches. Official information indicates that the treatment is intended to manage the symptoms of nausea and vomiting of pregnancy.

Q: Can Bonjesta be taken with over-the-counter pain relievers like Tylenol (acetaminophen)?

A: Regulatory warnings focus on combinations with central nervous system (CNS) depressants, such as alcohol, sedating medications, and certain other drugs, due to the risk of increased drowsiness. Acetaminophen (Tylenol) is not specifically listed in official regulatory documentation as a contraindicated combination or warning within the CNS depressant drug class.

Q: Is Bonjesta available in generic form?

A: According to official regulatory records, a generic version of the specific extended-release formulation of Bonjesta (doxylamine succinate 20 mg/pyridoxine hydrochloride 20 mg) is not currently available.

Q: Can Bonjesta be taken while breastfeeding?

A: Official prescribing information states that use of Bonjesta is not recommended for women who are breastfeeding. This is due to the doxylamine component being known to pass into breast milk, which may pose a potential risk of adverse effects like sedation or irritability in the infant.

Q: What is the active ingredient pyridoxine in Bonjesta?

A: Pyridoxine hydrochloride is one of the two active ingredients in Bonjesta. This ingredient is a form of Vitamin B₆, which complements the action of the antihistamine component.

Q: What is the active ingredient doxylamine in Bonjesta?

A: Doxylamine succinate is the second active ingredient in Bonjesta. This component is classified as a first-generation antihistamine, which contributes to the drug's anti-nausea effects.

Q: Can Bonjesta be used for nausea from causes other than pregnancy?

A: The official indication for this prescription medicine is strictly limited to the treatment of nausea and vomiting of pregnancy (NVP) after initial, conservative measures have failed. It is not indicated for the treatment of nausea or vomiting caused by other medical conditions or circumstances.

Q: Does taking Bonjesta affect the results of any medical tests?

A: Official warnings note that the doxylamine succinate component has been associated with reports of false positive results in urine screening tests for certain substances. These substances include methadone, opiates, and PCP.

Q: Does Bonjesta affect blood pressure?

A: In regulatory documents, changes in blood pressure are not listed among the commonly or frequently reported adverse reactions associated with the use of Bonjesta.

Q: Does Bonjesta cause any issues with driving or operating machinery?

A: The potential for somnolence, or drowsiness, is a documented side effect of Bonjesta. Official labeling contains warnings regarding engaging in activities requiring complete mental alertness, such as driving or operating heavy machinery, until the individual is aware of how the medicine affects them.

Q: What types of allergic reactions are associated with Bonjesta?

A: Official labeling contraindicates the use of Bonjesta in women who have known hypersensitivity—a type of allergic reaction—to any of the active ingredients or related antihistamines. However, the regulatory documentation does not provide details on specific types or frequency of generalized allergic reactions.

Q: What is the risk category of Bonjesta for use during pregnancy?

A: Regulatory agencies no longer use the former letter categories (A, B, C, D, X) for this medicine. The official Risk Summary notes that epidemiological studies have not reported an increased risk for congenital malformations (birth defects) when the drug combination is used during pregnancy.

Q: Can Bonjesta be split or crushed?

A: The extended-release tablet should be swallowed whole according to administration guidance. The regulatory guidance is explicit that the tablet should not be crushed, chewed, or split to maintain the drug's intended release profile.

Q: Why is the daily dosage of Bonjesta limited?

A: The maximum recommended dosage is limited to two tablets per day. This limitation is defined by regulatory authorities to balance the effectiveness of the treatment with the potential for dose-related side effects, especially the central nervous system (CNS) depressant effects of the doxylamine ingredient.

Q: Does Bonjesta cause weight gain or loss?

A: Weight gain or weight loss are not listed among the common or frequently reported adverse reactions documented in the official regulatory documentation for Bonjesta.

Q: Does Bonjesta help with heartburn or acid reflux as well?

A: Bonjesta is specifically indicated for the treatment of nausea and vomiting associated with pregnancy. It is not approved or indicated for the treatment of unrelated conditions such as heartburn or acid reflux.

Q: Can Bonjesta cause mood changes or depression?

A: Mood changes or depression are not listed among the common or frequently reported adverse reactions documented in the official regulatory documentation.

Q: What is the maximum duration a person typically uses Bonjesta?

A: The official label notes that the need for Bonjesta should be reassessed as the pregnancy progresses, and a specific maximum duration of use is not defined in the prescribing information.

Q: Is Bonjesta a controlled substance?

A: Bonjesta (doxylamine succinate and pyridoxine hydrochloride) is not classified as a controlled substance under the U.S. Controlled Substances Act.

Q: How long does it typically take for Bonjesta to start working?

A: Bonjesta is an extended-release tablet designed to provide sustained relief. When taken on an empty stomach, the doxylamine component reaches its peak concentration in the body in approximately 3.5 hours (median time), which is part of its sustained-action design.

Q: Is Bonjesta safe to take long-term?

A: The medicine is intended for use throughout pregnancy as needed to manage symptoms of NVP. The official label does not contain a specific time limit for use, but guidance states the need for the medicine should be reassessed as the pregnancy progresses.

Q: Is it possible to take Bonjesta only as needed, rather than every day?

A: Official administration guidelines state that Bonjesta is intended for continuous, daily administration to provide sustained relief, and should not be taken on an 'as needed' basis.

Q: What is the difference between Bonjesta and taking doxylamine and pyridoxine separately?

A: Bonjesta is a single, fixed-dose, extended-release tablet that combines both active ingredients to ensure a specific, sustained drug-release profile. Taking the ingredients separately typically involves two distinct over-the-counter products which do not have the same specific extended-release characteristics.

Q: Can Bonjesta cause stomach upset?

A: The official documentation lists specific gastrointestinal adverse reactions, such as dry mouth, constipation, and abdominal pain. It does not use the general, non-specific term 'stomach upset' in the description of common side effects.

Q: Is it possible to become dependent on Bonjesta?

A: Bonjesta is not classified as a controlled substance. Official regulatory documentation does not list drug dependence or abuse potential as a prominent warning or commonly reported adverse effect.

Q: Does Bonjesta interact with any common anti-depressant medications?

A: Official information contraindicates the use of Bonjesta with Monoamine Oxidase (MAO) inhibitors. Additionally, the label warns against combining the medicine with other central nervous system (CNS) depressants, which can include certain types of anti-depressants, due to the risk of additive drowsiness.

Q: Are there specific symptoms of severe morning sickness that Bonjesta is approved for?

A: Bonjesta is indicated for Nausea and Vomiting of Pregnancy (NVP) whose symptoms are not controlled by conservative management. The official label explicitly notes a limitation: the medication has not been studied for use in the most severe condition, which is known as hyperemesis gravidarum.

How should Bonjesta be stored and disposed of?

How to Store and Dispose of Bonjesta

Proper storage and handling ensure the effectiveness and safety of your medication. Bonjesta extended-release tablets must be stored at controlled room temperature, specifically between 68 F and 77 F (20 C and 25 C). Brief temperature excursions are permitted, ranging from 59 F to 86 F (15 C to 30 C).

Protect the tablets from moisture by keeping them in the original bottle, which contains a desiccant canister. The bottle cap should be closed tightly after each use, and the desiccant must not be removed.

Keep Bonjesta and all medications out of the reach of children.

For disposal, safely throw away any medicine that is expired or no longer required. Consult a healthcare professional or pharmacist on the proper method for discarding unused medication.

Bonjesta